Scinai Immunotherapeutics (SCNI) Notes Payables (2021 - 2022)
Scinai Immunotherapeutics (SCNI) reported Notes Payables of $382000.0 for Q4 2022, up 1.87% on a YoY basis from $375000.0 in Q4 2021, and up 1.87% sequentially from $375000.0 in Q4 2021.
Scinai Immunotherapeutics (SCNI) Notes Payables (2021 - 2022) Analysis & Trends
Scinai Immunotherapeutics (SCNI) has 2 years of Notes Payables data on file, last reported at $382000.0 in Q4 2022.
- For the quarter ending Q4 2022, Notes Payables rose 1.87% year-over-year to $382000.0; the trailing twelve-month figure through Dec 2022 stood at $382000.0 (up 1.87% YoY), and the FY2022 full-year result was $382000.0, up 1.87% from the prior year.
- Notes Payables advanced to $382000.0 in Q4 2022, from $375000.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $382000.0 in Q4 2022 to a low of $375000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Scinai Immunotherapeutics | 352,860.00 | -3.11 Bn | -1.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 382,000.00 |
| Dec 31, 2021 | 375,000.00 |